<DOC>
	<DOCNO>NCT02662283</DOCNO>
	<brief_summary>This prospective , randomize , control , multi-center clinical trial evaluate effect security reh-acteoside therapy patient IgA nephropathy .</brief_summary>
	<brief_title>Validity Security Reh-acteoside Therapy Patients IgA Nephropathy</brief_title>
	<detailed_description>Reh-acteoside ( general acteoside rehmanniae leave ) contain 10 kind bio-active mucopolysaeccharide , among acteoside effective ingredient , constitute 30 percent . It report acteoside reduce mesangium lesion IgA nephrology-model ddy-mice , mainly reduce express TGF-β1 , reduce proliferation mesangial cell glomerular sclerosis . Research also suggest conjunctive use reh-acteoside benazepril show well effect reduce proteinurine single use benazepril , obvious side effect time . Thus , start clinical trial evaluate effect security reh-acteoside therapy patient IgA nephropathy . We set 3 group : methylprednisolone group , reh-acteoside group methylprednisolone reh-acteoside group . After followed-up 8 week , remission proteinuria change renal function evaluate .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Acteoside</mesh_term>
	<criteria>Age 14~70 year , regardless gender Clinical evaluation renal biopsy diagnostic IgA nephropathy . Average urinary protein excretion 1.0~3.5g/24h two successive examination . eGFR ≥ 50 ml/min/1.73 m2 Willingness sign inform consent ( patient 18 year old need legal guardian sign ) . Secondary IgAN systemic lupus erythematosus , HenochSchonlein purpuric nephritis hepatitis B associate nephritis . Rapidly progressive nephritic syndrome ( crescent formation≥50 % ) . Acute renal failure , include rapidly progressive IgAN . Renal biopsy suggest active pathological change ( cellular crescent , loop necrosis , microthrombosis formation ) Current recent ( within 30 day ) exposure steroid immunosuppressive therapy ( CTX、MMF、CsA、FK506 ) . Recent acute hepatitis ( 2 week ) , chronic active hepatitis ( hepatitis B hepatitis C infection ) , rise 2.5 fold current ALT , AST TBil level . History significant gastrointestinal disorder ( e.g . severe chronic diarrhea active peptic ulcer disease ) . Any Active systemic infection history serious infection within one month . Other major organ system disease ( e.g . serious cardiovascular disease include congestive heart failure , chronic obstructive pulmonary disease , asthma require oral steroid treatment central nervous system disease ) . Active tuberculosis Malignant hypertension difficult control oral drug . Known allergy , contraindication intolerance steroid . Pregnancy breast feeding time entry unwillingness comply measure contraception . Malignant tumor Excessive drink drug abuse Mental aberration Current recent ( within 30 day ) exposure investigational drug .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>IGA Nephropathy</keyword>
	<keyword>proteinurien</keyword>
	<keyword>Reh-acteoside</keyword>
	<keyword>Prednisolone</keyword>
</DOC>